Payment overview · 2025
General Payments
$613.76
19 reported records · 9 companies
Healthcare provider profile · identity verified
Wanda M Berrios, MD
Allopathic & Osteopathic Physicians|Family Medicine · KISSIMMEE, FL · NPI 1932216496
Verified facts
What the public records show
CMS Open Payments records show Wanda M Berrios, MD received $613.76 in general payments during 2025 across 19 reported records.
AstraZeneca Pharmaceuticals LP accounted for 38.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Otezla, Ozempic, Paxlovid, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $235.59 | 38.4% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $108.71 | 17.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $75.60 | 12.3% | 3 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $47.47 | 7.7% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.30 | 7.2% | 2 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $35.90 | 5.8% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.34 | 4.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.79 | 3.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $16.06 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $613.76 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $181.65 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $108.71 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $85.99 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $47.85 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $44.30 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $35.90 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $32.05 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $29.34 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.79 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $17.41 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $16.06 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 127 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 141 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 69 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 24 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
141 | 36 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 27 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
69 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
127 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
24 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 767 | 230 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 733 | 237 |
| Amlodipine Besylate | Amlodipine Besylate | 502 | 152 |
| Lisinopril | Lisinopril | 493 | 144 |
| Fluticasone Propionate | Fluticasone Propionate | 464 | 237 |
| Losartan Potassium | Losartan Potassium | 419 | 138 |
| Levothyroxine Sodium | Levothyroxine Sodium | 405 | 108 |
| Metformin Hcl | Metformin Hcl | 390 | 126 |
| Famotidine | Famotidine | 380 | 135 |
| Gabapentin | Gabapentin | 360 | 151 |
| Alendronate Sodium | Alendronate Sodium | 260 | 85 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 234 | 81 |
| Montelukast Sodium | Montelukast Sodium | 229 | 76 |
| Pantoprazole Sodium | Pantoprazole Sodium | 228 | 74 |
| Ezetimibe | Ezetimibe | 225 | 75 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 63 |
| Omeprazole | Omeprazole | 213 | 77 |
| Clopidogrel | Clopidogrel Bisulfate | 196 | 58 |
| Carvedilol | Carvedilol | 191 | 58 |
| Simvastatin | Simvastatin | 187 | 54 |
| Tizanidine Hcl | Tizanidine Hcl | 185 | 97 |
| Hydrochlorothiazide | Hydrochlorothiazide | 169 | 55 |
| Glipizide | Glipizide | 168 | 49 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 155 | 45 |
| Trazodone Hcl | Trazodone Hcl | 149 | 57 |
| Methocarbamol | Methocarbamol | 144 | 81 |
| Farxiga | Dapagliflozin Propanediol | 141 | 36 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 140 | 63 |
| Tamsulosin Hcl | Tamsulosin Hcl | 132 | 47 |
| Fenofibrate | Fenofibrate,micronized | 128 | 43 |
| Eliquis | Apixaban | 127 | 37 |
| Azelastine Hcl | Azelastine Hcl | 126 | 75 |
| Metoprolol Tartrate | Metoprolol Tartrate | 124 | 40 |
| Buspirone Hcl | Buspirone Hcl | 122 | 38 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 112 | 97 |
| Ibuprofen | Ibuprofen | 111 | 53 |
| Diclofenac Sodium | Diclofenac Sodium | 99 | 52 |
| Hydralazine Hcl | Hydralazine Hcl | 96 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 93 | 37 |
| Furosemide | Furosemide | 90 | 34 |
| Prednisone | Prednisone | 90 | 59 |
| Azithromycin | Azithromycin | 87 | 81 |
| Meloxicam | Meloxicam | 84 | 40 |
| Donepezil Hcl | Donepezil Hcl | 82 | 28 |
| Amitriptyline Hcl | Amitriptyline Hcl | 79 | 20 |
| Sucralfate | Sucralfate | 78 | 26 |
| Allopurinol | Allopurinol | 74 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 72 | 22 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 71 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 70 | 25 |
| Jardiance | Empagliflozin | 69 | 27 |
| Ozempic | Semaglutide | 69 | 15 |
| Clonidine Hcl | Clonidine Hcl | 67 | 25 |
| Synthroid | Levothyroxine Sodium | 64 | 14 |
| Spironolactone | Spironolactone | 63 | 17 |
| Lactulose | Lactulose | 62 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 19 |
| Nitroglycerin | Nitroglycerin | 61 | 23 |
| Sertraline Hcl | Sertraline Hcl | 60 | 22 |
| Bumetanide | Bumetanide | 58 | 21 |
| Lovastatin | Lovastatin | 58 | 20 |
| Nabumetone | Nabumetone | 57 | 36 |
| Glipizide Er | Glipizide | 56 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 56 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | 18 |
| Dicyclomine Hcl | Dicyclomine Hcl | 55 | 27 |
| Mirtazapine | Mirtazapine | 54 | 23 |
| Finasteride | Finasteride | 51 | 18 |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 51 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 18 |
| Dexamethasone | Dexamethasone | 50 | 46 |
| Fenofibrate | Fenofibrate | 50 | 15 |
| Januvia | Sitagliptin Phosphate | 48 | 18 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Atenolol | Atenolol | 44 | 15 |
| Sildenafil Citrate | Sildenafil Citrate | 44 | 15 |
| Temazepam | Temazepam | 44 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 43 | 13 |
| Calcitriol | Calcitriol | 42 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 40 | 12 |
| Tradjenta | Linagliptin | 40 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 24 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 39 | 16 |
| Cephalexin | Cephalexin | 38 | 35 |
| Ketoconazole | Ketoconazole | 38 | 24 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 38 | 12 |
| Trulicity | Dulaglutide | 38 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 37 | 12 |
| Benazepril Hcl | Benazepril Hcl | 36 | suppressed |
| Celecoxib | Celecoxib | 36 | 18 |
| Irbesartan | Irbesartan | 36 | 11 |
| Novolog Flexpen | Insulin Aspart | 36 | 11 |
| Topiramate | Topiramate | 36 | suppressed |
| Potassium Chloride | Potassium Chloride | 35 | 15 |
| Baclofen | Baclofen | 34 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 34 | suppressed |
| Naproxen | Naproxen | 34 | 19 |
| Latanoprost | Latanoprost | 33 | 18 |
| Mupirocin | Mupirocin | 33 | 29 |
| Valsartan | Valsartan | 32 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 31 | 16 |
| Metformin Hcl Er | Metformin Hcl | 31 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 31 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 30 | suppressed |
| Methotrexate | Methotrexate Sodium | 30 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 30 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 29 | 11 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 28 | 13 |
| Ibandronate Sodium | Ibandronate Sodium | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 25 |
| Alprazolam | Alprazolam | 27 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 20 |
| Cholestyramine | Cholestyramine (With Sugar) | 26 | suppressed |
| Metronidazole | Metronidazole | 26 | 11 |
| Pregabalin | Pregabalin | 26 | 12 |
| Vascepa | Icosapent Ethyl | 26 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 25 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Fluconazole | Fluconazole | 24 | 22 |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 24 | suppressed |
| Methylprednisolone | Methylprednisolone | 24 | 23 |
| Mometasone Furoate | Mometasone Furoate | 24 | 17 |
| Paxlovid | Nirmatrelvir/Ritonavir | 24 | 23 |
| Prolia | Denosumab | 24 | 19 |
| Symbicort | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Anastrozole | Anastrozole | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 23 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 23 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Folic Acid | Folic Acid | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 20 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 12 |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 17 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Nifedipine Er | Nifedipine | 16 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 14 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 15 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Rybelsus | Semaglutide | 15 | suppressed |
| Torsemide | Torsemide | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Leflunomide | Leflunomide | 14 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 14 | suppressed |
| Sulfasalazine | Sulfasalazine | 14 | suppressed |
| Timolol Maleate | Timolol Maleate | 14 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | 11 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 13 | suppressed |
| Insulin Lispro | Insulin Lispro | 13 | suppressed |
| Otezla | Apremilast | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 13 |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | 11 |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Trandolapril | Trandolapril | 12 | suppressed |
| Benzonatate | Benzonatate | 11 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Clonazepam | Clonazepam | 11 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $613.76 · 19 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, ELIQUIS, FARXIGA, Kerendia, Korlym, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PAXLOVID, REPATHA, Rybelsus, XHANCE | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error